Cite
HARVARD Citation
Fink, A. et al. (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet. 4 (10), pp. e475-e486. [Online].